Brokerages Set Vivos Therapeutics, Inc. (NASDAQ:VVOS) PT at $4.92

Vivos Therapeutics, Inc. (NASDAQ:VVOS) has been assigned an average recommendation of “Hold” from the five brokerages that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $4.9167.

Several brokerages have recently weighed in on VVOS. Zacks Research upgraded Vivos Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, December 1st. Weiss Ratings reissued a “sell (e+)” rating on shares of Vivos Therapeutics in a research report on Wednesday, January 21st. Finally, Ascendiant Capital Markets lowered their price target on Vivos Therapeutics from $6.50 to $5.50 and set a “buy” rating on the stock in a research report on Wednesday, December 3rd.

Hedge Funds Weigh In On Vivos Therapeutics

A number of institutional investors have recently added to or reduced their stakes in VVOS. Connective Capital Management LLC bought a new stake in Vivos Therapeutics during the third quarter worth $620,000. DRW Securities LLC increased its stake in shares of Vivos Therapeutics by 179.5% during the 4th quarter. DRW Securities LLC now owns 115,907 shares of the company’s stock worth $235,000 after purchasing an additional 74,441 shares during the last quarter. B. Riley Wealth Advisors Inc. acquired a new position in shares of Vivos Therapeutics during the 2nd quarter worth about $220,000. XTX Topco Ltd bought a new stake in shares of Vivos Therapeutics in the 2nd quarter valued at about $65,000. Finally, Acorn Wealth Advisors LLC bought a new stake in shares of Vivos Therapeutics in the 4th quarter valued at about $30,000. 26.35% of the stock is currently owned by institutional investors and hedge funds.

Vivos Therapeutics Stock Down 2.5%

Shares of VVOS stock opened at $1.15 on Friday. The firm’s fifty day moving average price is $1.55 and its two-hundred day moving average price is $2.25. The company has a current ratio of 0.78, a quick ratio of 0.78 and a debt-to-equity ratio of 3.31. Vivos Therapeutics has a 1 year low of $1.12 and a 1 year high of $7.95. The firm has a market capitalization of $12.04 million, a P/E ratio of -0.65 and a beta of 6.94.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.